Statins, inexpensive prescription oral medications that lower blood cholesterol, are used to prevent heart attacks and strokes. The strongest evidence shows fewer heart attacks, strokes and artery-opening procedures, plus a smaller drop in overall deaths. Main harms are a modest blood-sugar rise, mild liver enzyme changes and a small excess of muscle aches. In people over seventy, more years free of dementia or disability were not shown. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL-C | Below 100, 70 or 55 mg/dL by risk | Main efficacy marker |
| Non-HDL-C | Below 130 or 100 mg/dL by risk | Captures all cholesterol in plaque-forming particles |
| ApoB | Below 100, 80 or 65 mg/dL by risk | Counts plaque-forming particles directly |
| Lp(a) | Below 125 nmol/L (below 50 mg/dL) | Statins raise it modestly |
| ALT | 7–55 U/L | Safety check; serious elevation stops use |
| CK | Men 39–308 U/L; women 26–192 U/L | Safety check; above 10 times the upper limit with symptoms stops use |
| HbA1c | 4.0–5.6% | Safety check; detects statin-related glucose rise |
| eGFR / creatinine | eGFR 60 mL/min/1.73 m² or higher | Safety check; low values change dose |
| TSH | 0.4–4.0 mIU/L | Safety check; untreated hypothyroidism raises myopathy risk |
| hs-CRP | No established target; track change from own baseline | Statins lower it |
Cadence: Baseline lipid panel with apoB, one-time Lp(a), liver enzymes, HbA1c, kidney and thyroid function; lipid panel and apoB 4–12 weeks after starting or changing dose, then every 6–12 months; HbA1c at 3–12 months, then yearly; liver enzymes, CK and kidney function only when symptoms or new interacting drugs arise.